Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM
Fu-Shun Yen , James Cheng-Chung Wei , Ying-Hsiu Shih , Yu-Tung Hung , Tzu-Ju Hsu , Chih-Cheng Hsu , Chii-Min Hwu
{"title":"Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study","authors":"Fu-Shun Yen ,&nbsp;James Cheng-Chung Wei ,&nbsp;Ying-Hsiu Shih ,&nbsp;Yu-Tung Hung ,&nbsp;Tzu-Ju Hsu ,&nbsp;Chih-Cheng Hsu ,&nbsp;Chii-Min Hwu","doi":"10.1016/j.dsx.2024.103099","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>To compare the risk of vision-threatening retinopathy between glucagon-like peptide-1 receptor agonists (GLP-1 RA) use and no use in patients with type 2 diabetes.</p></div><div><h3>Methods</h3><p>Using propensity score matching, we identified 27,506 pairs of GLP-1 RA users and non-users, 3904 pairs of GLP-1 RA and dipeptidyl peptidase-4 inhibitors (DPP-4i) users, 10,985 pairs of GLP-1 RA and sodium-glucose cotransporter-2 inhibitors (SGLT2i) users, 2542 pairs of GLP-1 RA and sulfonylurea, respectively, from Taiwan's National Health Insurance Research Database from January 1, 2009 to December 31, 2018. We used Cox proportional hazards models to compare the risk of vision-threatening retinopathy between GLP-1 RA use and other matched groups.</p></div><div><h3>Results</h3><p>In the matched cohorts, the time-varying exposure analysis showed that GLP-1 RA use was not associated with an increased risk of vision-threatening retinopathy compared to GLP-1 RA non-use (aHR 0.96, 95 % CI 0.89–1.03). New-user and active-comparator analyses showed that GLP-1 RA was associated with a significantly lower risk of vision-threatening retinopathy than DPP-4i (aHR 0.8, 95 % CI 0.66–0.97) but had no significant association with this risk compared to SGLT2i (aHR 1.09, 95 % CI 0.96–1.24) or sulfonylureas (aHR 0.79, 95 % CI 0.49–1.06).</p></div><div><h3>Conclusions</h3><p>This nationwide cohort study showed that GLP-1 RA use was not associated with an increased risk of vision-threatening retinopathy compared to non- GLP-1 RA use, and GLP-1 RA could significantly lower the risk of vision-threatening retinopathy than DPP-4i.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103099"},"PeriodicalIF":4.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1871402124001607","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims

To compare the risk of vision-threatening retinopathy between glucagon-like peptide-1 receptor agonists (GLP-1 RA) use and no use in patients with type 2 diabetes.

Methods

Using propensity score matching, we identified 27,506 pairs of GLP-1 RA users and non-users, 3904 pairs of GLP-1 RA and dipeptidyl peptidase-4 inhibitors (DPP-4i) users, 10,985 pairs of GLP-1 RA and sodium-glucose cotransporter-2 inhibitors (SGLT2i) users, 2542 pairs of GLP-1 RA and sulfonylurea, respectively, from Taiwan's National Health Insurance Research Database from January 1, 2009 to December 31, 2018. We used Cox proportional hazards models to compare the risk of vision-threatening retinopathy between GLP-1 RA use and other matched groups.

Results

In the matched cohorts, the time-varying exposure analysis showed that GLP-1 RA use was not associated with an increased risk of vision-threatening retinopathy compared to GLP-1 RA non-use (aHR 0.96, 95 % CI 0.89–1.03). New-user and active-comparator analyses showed that GLP-1 RA was associated with a significantly lower risk of vision-threatening retinopathy than DPP-4i (aHR 0.8, 95 % CI 0.66–0.97) but had no significant association with this risk compared to SGLT2i (aHR 1.09, 95 % CI 0.96–1.24) or sulfonylureas (aHR 0.79, 95 % CI 0.49–1.06).

Conclusions

This nationwide cohort study showed that GLP-1 RA use was not associated with an increased risk of vision-threatening retinopathy compared to non- GLP-1 RA use, and GLP-1 RA could significantly lower the risk of vision-threatening retinopathy than DPP-4i.

台湾人群中的胰高血糖素样肽-1 受体激动剂与危及视力的视网膜病变风险:基于倾向的队列研究
目的:比较2型糖尿病患者使用和不使用胰高血糖素样肽-1受体激动剂(GLP-1 RA)发生视力威胁性视网膜病变的风险:使用倾向得分匹配法,我们从2009年1月1日至2018年12月31日的台湾国民健康保险研究数据库中分别识别出27506对GLP-1 RA使用者和非使用者、3904对GLP-1 RA和二肽基肽酶-4抑制剂(DPP-4i)使用者、10985对GLP-1 RA和钠-葡萄糖共转运体-2抑制剂(SGLT2i)使用者、2542对GLP-1 RA和磺脲类药物使用者。我们使用Cox比例危险模型比较了使用GLP-1 RA和其他匹配组之间发生威胁视力的视网膜病变的风险:在匹配队列中,时变暴露分析表明,与不使用 GLP-1 RA 相比,使用 GLP-1 RA 与视力威胁性视网膜病变风险增加无关(aHR 0.96,95 % CI 0.89-1.03)。新用户和活跃比较者分析表明,与DPP-4i相比,GLP-1 RA与威胁视力的视网膜病变风险显著降低(aHR 0.8,95 % CI 0.66-0.97),但与SGLT2i(aHR 1.09,95 % CI 0.96-1.24)或磺脲类药物(aHR 0.79,95 % CI 0.49-1.06)相比,GLP-1 RA与该风险无显著关联:这项全国性队列研究表明,与不使用 GLP-1 RA 的患者相比,使用 GLP-1 RA 与视力威胁性视网膜病变风险的增加无关,而且 GLP-1 RA 比 DPP-4i 能显著降低视力威胁性视网膜病变的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
22.90
自引率
2.00%
发文量
248
审稿时长
51 days
期刊介绍: Diabetes and Metabolic Syndrome: Clinical Research and Reviews is the official journal of DiabetesIndia. It aims to provide a global platform for healthcare professionals, diabetes educators, and other stakeholders to submit their research on diabetes care. Types of Publications: Diabetes and Metabolic Syndrome: Clinical Research and Reviews publishes peer-reviewed original articles, reviews, short communications, case reports, letters to the Editor, and expert comments. Reviews and mini-reviews are particularly welcomed for areas within endocrinology undergoing rapid changes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信